Can immunotherapy specifically target acute myeloid leukemic stem cells?

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Snauwaert, Sylvia ^a   Vandekerckhove, Bart ^a   Kerre, Tessa ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute myeloid leukemia; Adoptive T cell therapy; Immunotherapy; Leukemia associated antigen; Leukemic stem cell; Therapeutic antibodies

Indexed keywords

CD123 ANTIBODY; DACLIZUMAB; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL PRACTICE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOPHENOTYPING; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR MICROENVIRONMENT;

EID: 84886944498     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22943     Document Type: Review

References (85)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006; 368:1894-907; http://dx.doi.org/10.1016/S0140-6736(06)69780-8.
2. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009; 5:31-42; http://dx.doi.org/10.1016/j.stem.2009.04.018.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8; http://dx.doi.org/10.1038/367645a0.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; http://dx.doi.org/10.1038/nm0797-730.
5. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12:1167-74; http://dx.doi.org/10.1038/nm1483.
6. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11:6520-7; http://dx.doi.org/10.1158/1078-0432.CCR-05-0468.
7. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2009 Mar 3;106(9):3396-401. PubMed.
8. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proceedings of the National Academy of Sciences of the United States of America. 2003 Sep 30;100 Suppl 1:11842-9.
9. Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985; 75:746-53; http://dx.doi.org/10.1172/JCI111756.
10. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; http://dx.doi.org/10.1038/nm0797-730.
11. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94:1761-72; PMID:10477702.
12. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25:1315-21; http://dx.doi.org/10.1038/nbt1350.
13. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-9; http://dx.doi.org/10.1182/blood-2002-10-3062.
14. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17:1086-93; http://dx.doi.org/10.1038/nm.2415.
15. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibodymediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112:568-75; http://dx.doi.org/10.1182/blood-2007-10-118331.
16. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115:1976-84; http://dx.doi.org/10.1182/blood-2009-02-206565.
17. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000; 14:889-97; http://dx.doi.org/10.1038/sj.leu.2401777.
18. Scadden DT. Cancer stem cells refined. Nat Immunol 2004; 5:701-3; http://dx.doi.org/10.1038/ni0704-701.
19. Greaves M. Cancer stem cells renew their impact. Nat Med 2011; 17:1046-8; http://dx.doi.org/10.1038/nm.2458.
20. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107:1166-73; http://dx.doi.org/10.1182/blood-2005-06-2325.
21. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304:2706-15; http://dx.doi.org/10.1001/jama.2010.1862.
22. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23:752-60; http://dx.doi.org/10.1634/stemcells.2004-0292.
23. Schubert M, Herbert N, Taubert I, Ran D, Singh R, Eckstein V, et al. Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol 2011; 39:250-63e4; http://dx.doi.org/10.1016/j.exphem.2010.10.010.
24. Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008; 26:3059-67; http://dx.doi.org/10.1634/stemcells.2007-0861.
25. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, et al. Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21:1700-7; http://dx.doi.org/10.1038/sj.leu.2404754.
26. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010; 2:17ra9; http://dx.doi.org/10.1126/scitranslmed.3000349.
27. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110:2659-66; http://dx.doi.org/10.1182/blood-2007-03-083048.
28. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99; http://dx.doi.org/10.1016/j.cell.2009.05.045.
29. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cellspecific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2007 Jun 26;104(26):11008-13.
30. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20:2147-54; http://dx.doi.org/10.1038/sj.leu.2404401.
31. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-43;; http://dx.doi.org/10.1038/ni1080.
32. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28:275-80; PMID:20160717.
33. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327:1650-3; http://dx.doi.org/10.1126/science.1186624.
34. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9:1158-65; http://dx.doi.org/10.1038/nm909.
35. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8:399-411; http://dx.doi.org/10.1016/j.stem.2011.02.006.
36. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359:613-26; http://dx.doi.org/10.1056/NEJMra0708875.
37. Liu J, Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol 2006; 3:359-65.
38. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138:271-85; http://dx.doi.org/10.1016/j.cell.2009.05.046.
39. Kaname T, Yanagi K, Chinen Y, Makita Y, Okamoto N, Maehara H, et al. Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome. Am J Hum Genet 2007; 81:835-41; http://dx.doi.org/10.1086/522014.
40. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193:855-62; http://dx.doi.org/10.1084/jem.193.7.855.
41. Wang PL, O'Farrell S, Clayberger C, Krensky AM. Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol 1992; 148:2600-8.
42. Nashan B, Light S, Hardie IR, Lin A, Johnson JR; Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67:110-5; http://dx.doi.org/10.1097/00007890-199901150-00019.
43. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al.; Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338:161-5; http://dx.doi.org/10.1056/NEJM199801153380304.
44. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106:4086-92; http://dx.doi.org/10.1182/blood-2005-03-1072.
45. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al.; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-54.
46. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010; 24:74-80; http://dx.doi.org/10.1038/leu.2009.199.
47. Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectinlike molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64:8443-50; http://dx.doi.org/10.1158/0008-5472.CAN-04-1659.
48. Roberts AW, He S, Bradstock KF, Hertzberg MS, Durrant STS, Ritchie D, et al. A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. Blood 2008; 112(2956a).
49. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442-52; http://dx.doi.org/10.1002/cncr.21326.
50. Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al.; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010; 115:2586-91;http://dx.doi.org/10.1182/blood-2009-10-246470.
51. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149:376-82; http://dx.doi.org/10.1111/j.1365-2141.2010.08095.x.
52. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006; 13:26-41; http://dx.doi.org/10.1016/j.ymthe.2005.09.011.
53. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al.; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041-50.
54. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068-73;http://dx.doi.org/10.1056/NEJM197905103001902.
55. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graftversus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1529-33; http://dx.doi.org/10.1056/NEJM198106183042507.
56. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. [eng.]. Proc Natl Acad Sci U S A 2003; 100:2742-7; http://dx.doi.org/10.1073/pnas.0530192100.
57. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18:798-808; http://dx.doi.org/10.1038/sj.leu.2403297.
58. Kapp M, Stevanović S, Fick K, Tan SM, Loeffler J, Opitz A, et al. CD8+ T-cell responses to tumorassociated antigens correlate with superior relapsefree survival after allo-SCT. Bone Marrow Transplant 2009; 43:399-410; http://dx.doi.org/10.1038/bmt.2008.426.
59. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006; 18:599-604; http://dx.doi.org/10.1016/j.coi.2006.07.005.
60. Ramírez F, Ghani Y, Gao L, Stauss H. Dendritic cell immunization induces Nonprotective WT1-specific CTL responses in mouse. [eng.]. J Immunother 2007; 30:140-9; http://dx.doi.org/10.1097/01.cji.0000211328.76266.81.
61. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. [eng.]. Proc Natl Acad Sci U S A 1996; 93:13114-8; http://dx.doi.org/10.1073/pnas.93.23.13114.
62. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
63. Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, et al. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica 2012; 97:1539-47; http://dx.doi.org/10.3324/haematol.2012.065581.
64. Fatrai S, Schepers H, Tadema H, Vellenga E, Daenen SM, Schuringa JJ. Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol 2008; 36:1254-65; http://dx.doi.org/10.1016/j.exphem.2008.04.015.
65. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423:255-60; http://dx.doi.org/10.1038/nature01572.
66. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al. MHC-restricted fratricide of human lymphocytes expressing survivinspecific transgenic T cell receptors. J Clin Invest 2010; 120:3869-77; http://dx.doi.org/10.1172/JCI43437.
67. Nagai K, Ochi T, Fujiwara H, An J, Shirakata T, Mineno J, et al. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood 2012; 119:368-76; http://dx.doi.org/10.1182/blood-2011-06-360354.
68. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010; 116:1498-505; http://dx.doi.org/10.1182/blood-2009-11-251074.
69. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113:66-74; http://dx.doi.org/10.1182/blood-2008-06-164889.
70. Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, et al. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood 2012; 119:3440-9; http://dx.doi.org/10.1182/blood-2011-06-357939.
71. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17:1301-12; http://dx.doi.org/10.1038/sj.leu.2402988.
72. Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 2003; 75:1429-36; http://dx.doi.org/10.1097/01.TP.0000061516.57346.E8.
73. Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95:2198-203.
74. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille Sb, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences. 2009 August 3, 2010; 107(31):13824-9.
75. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113:6541-8; http://dx.doi.org/10.1182/blood-2009-02-202598.
76. Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Götz M, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012; 120:1282-9; http://dx.doi.org/10.1182/blood-2011-11-394395.
77. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87:4789-96.
78. Haase D, Feuring-Buske M, Könemann S, Fonatsch C, Troff C, Verbeek W, et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 1995; 86:2906-12.
79. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26:2186-96; http://dx.doi.org/10.1038/leu.2012.145.
80. Hofmann A, Gerrits B, Schmidt A, Bock T, Bausch-Fluck D, Aebersold R, et al. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood 2010; 116:e26-34; http://dx.doi.org/10.1182/blood-2010-02-271270.
81. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004; 45:1501-10; http://dx.doi.org/10.1080/1042819042000206687.
82. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14:1777-84; http://dx.doi.org/10.1038/sj.leu.2401903.
83. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. [eng.]. Haematologica 2008; 93:662-9; http://dx.doi.org/10.3324/haematol.12148.
84. Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001; 61:6846-50.
85. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. [eng.]. Blood 2005; 106:3062-7; http://dx.doi.org/10.1182/blood-2005-01-0146.